Paper39765351
[Clinical characteristics and treatment efficacy of newly diagnosed acute leukemia in the plateau].
He QY and 13 others. Zhonghua Xue Ye Xue Za Zhi, 2024. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. [Clinical characteristics and treatment efficacy of newly diagnosed acute leukemia in the plateau]. Papers, record 39765351. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39765351
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- [Clinical characteristics and treatment efficacy of newly diagnosed acute leukemia in the plateau].
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Major topic |
| Humans | |
| Retrospective Studies | |
| Prognosis | |
| Treatment Outcome | |
| Tibet | |
| Survival Analysis | |
| Male | |
| Female | |
| Survival Rate |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2022-RW320-14 | Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences | PubMed | ||
| 2023NCRCA0101 | Clinical Research Foundation of National Clinical Research Center for Blood Diseases | PubMed | ||
| 2021YFC2500300 | National Key Research and Development Program of China | PubMed |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22412151 | Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22412151 | PubMed |
| 2 | 37424223 | Novel precision medicine approaches and treatment strategies in hematological malignancies. | J Intern Med | 2023 | https://conductscience.org/library/papers/37424223 | PubMed |
| 3 | 34551384 | Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 | https://conductscience.org/library/papers/34551384 | PubMed |
| 4 | 35680595 | [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | https://conductscience.org/library/papers/35680595 | PubMed |
| 5 | 18502832 | What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. | Blood | 2008 | https://conductscience.org/library/papers/18502832 | PubMed |
| 6 | 29563537 | Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. | Leukemia | 2018 | https://conductscience.org/library/papers/29563537 | PubMed |
| 7 | 29562460 | [Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018)]. | Zhonghua Xue Ye Xue Za Zhi | 2018 | https://conductscience.org/library/papers/29562460 | PubMed |
| 8 | 24127444 | Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/24127444 | PubMed |
| 9 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 10 | 31113776 | The simpler, the better: oral arsenic for acute promyelocytic leukemia. | Blood | 2019 | https://conductscience.org/library/papers/31113776 | PubMed |
| 11 | 32461631 | Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. | Leukemia | 2020 | https://conductscience.org/library/papers/32461631 | PubMed |
| 12 | 33085860 | Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. | N Engl J Med | 2020 | https://conductscience.org/library/papers/33085860 | PubMed |
| 13 | 29905379 | Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. | Am J Hematol | 2018 | https://conductscience.org/library/papers/29905379 | PubMed |
| 14 | 23716539 | Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. | Haematologica | 2013 | https://conductscience.org/library/papers/23716539 | PubMed |
| 15 | 27276561 | Genomic Classification and Prognosis in Acute Myeloid Leukemia. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27276561 | PubMed |
| 16 | 16407512 | Treatment of acute lymphoblastic leukemia. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16407512 | PubMed |
| 17 | 31495127 | [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old]. | Zhonghua Xue Ye Xue Za Zhi | 2019 | https://conductscience.org/library/papers/31495127 | PubMed |
| 18 | 34193815 | Acute promyelocytic leukemia current treatment algorithms. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/34193815 | PubMed |
| 19 | 25871894 | Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers. | Chemotherapy | 2014 | https://conductscience.org/library/papers/25871894 | PubMed |
| 20 | 35834222 | Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. | JAMA Oncol | 2022 | https://conductscience.org/library/papers/35834222 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CEBPZ | 10153 | PubTator's text mining | https://conductscience.org/library/genes/10153 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39765351
GET https://conductscience.org/api/papers/v1/39765351/authors